{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:23:22Z","timestamp":1786112602859,"version":"build-2736575974"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cardiac diseases such as myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM) are common in dogs and are associated with progressive cardiac dysfunction and increased oxidative stress. Despite the widespread use of nutraceuticals in veterinary medicine, clinical evidence supporting their efficacy remains limited. This study aimed to evaluate the effects of a resveratrol-containing nutraceutical on cardiac biomarkers, echocardiographic parameters, oxidative stress, and safety in dogs with naturally occurring cardiac disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective, non-randomized, open-label study included 24 client-owned dogs allocated to a treatment group (\n                      <jats:italic>n<\/jats:italic>\n                      = 12) or a control group (\n                      <jats:italic>n<\/jats:italic>\n                      = 12). Dogs in the treatment group received a resveratrol-containing nutraceutical (with taurine, vitamin E, and coenzyme Q10) once daily for approximately one month, while control dogs received standard cardiac medications without nutraceutical supplementation. Cardiac biomarkers (NT-proBNP, cTnI), echocardiographic variables including global longitudinal strain (GLS), and oxidative stress markers (TAC, MDA) were evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The percent change in NT-proBNP was significantly lower in the treatment group than in controls (\u22124.51 \u00b1 46.21% vs. +44.61 \u00b1 62.36%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.024), indicating attenuation of NT-proBNP elevation. TAC increased in the treatment group but decreased in controls (7.85 \u00b1 7.07% vs. \u22128.00 \u00b1 5.31%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.0001). No significant between-group differences were observed for cTnI (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.164), GLS (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.214), or MDA (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.590). A significant negative association was observed between changes in TAC and NT-proBNP (\n                      <jats:italic>r<\/jats:italic>\n                      = \u22120.471,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.020). No clinically relevant adverse effects were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Findings from this exploratory pilot study suggest that a resveratrol-containing nutraceutical was associated with attenuation of NT-proBNP elevation and an increase in total antioxidant capacity in dogs with cardiac disease. These preliminary findings suggest a potential role for antioxidant-based nutraceuticals as adjunctive therapy, although further studies with larger populations and longer follow-up are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fvets.2026.1867081","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:22:46Z","timestamp":1785943366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of a resveratrol-containing nutraceutical on cardiac biomarkers, echocardiographic parameters, and oxidative stress in dogs with naturally occurring cardiac disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Dong-Yeong","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University","place":["Seoul, Republic of Korea"]},{"name":"Choonghyun Animal Hospital","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Myung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2460\/javma.2001.218.1755","article-title":"Evaluation of nutraceuticals, dietary supplements, and functional food ingredients for companion animals","volume":"218","author":"Bauer","year":"2001","journal-title":"J Am Vet Med Assoc"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/vetsci12100964","article-title":"Nutraceuticals, social interaction, and psychophysiological influence on pet health and well-being: focus on dogs and cats","volume":"12","author":"Nicotra","year":"2025","journal-title":"Vet Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.2460\/javma.232.11.1646","article-title":"An evidence-based review of the use of nutraceuticals and dietary supplementation for the management of obese and overweight pets","volume":"232","author":"Roudebush","year":"2008","journal-title":"J Am Vet Med Assoc"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/NT.0000000000000399","article-title":"Veterinary pet supplements and nutraceuticals","volume":"55","author":"Finno","year":"2020","journal-title":"Nutr Today"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jvc.2012.01.011","article-title":"Historical review, epidemiology and natural history of degenerative mitral valve disease","volume":"14","author":"Borgarelli","year":"2012","journal-title":"J Vet Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3390\/ani12131679","article-title":"Genetic basis of dilated cardiomyopathy in dogs and its potential as a bidirectional model","volume":"12","author":"Gaar-Humphreys","year":"2022","journal-title":"Animals (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1748-5827.2008.00659.x","article-title":"Canine dilated cardiomyopathy: a retrospective study of signalment, presentation and clinical findings in 369 cases","volume":"50","author":"Martin","year":"2009","journal-title":"J Small Anim Pract"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"skaa155","DOI":"10.1093\/jas\/skaa155","article-title":"Review of canine dilated cardiomyopathy in the wake of diet-associated concerns","volume":"98","author":"McCauley","year":"2020","journal-title":"J Anim Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/j.1939-1676.2009.0392.x","article-title":"Guidelines for the diagnosis and treatment of canine chronic valvular heart disease","volume":"23","author":"Atkins","year":"2009","journal-title":"J Vet Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/s1760-2734(06)70047-9","article-title":"Proposed guidelines for the diagnosis of canine idiopathic dilated cardiomyopathy","volume":"5","author":"Dukes-McEwan","year":"2003","journal-title":"J Vet Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/jvim.15488","article-title":"ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs","volume":"33","author":"Keene","year":"2019","journal-title":"J Vet Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.36628\/ijhf.2020.0002","article-title":"Angiotensin receptor\u2013neprilysin inhibition (ARNI) in heart failure","volume":"2","author":"Greenberg","year":"2020","journal-title":"Int J Heart Fail"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/jvim.15240","article-title":"A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril\/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease","volume":"32","author":"Newhard","year":"2018","journal-title":"J Vet Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/jvim.14586","article-title":"Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study","volume":"30","author":"Boswood","year":"2016","journal-title":"J Vet Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1939-1676.2005.tb02724.x","article-title":"Antioxidant status and biomarkers of oxidative stress in dogs with congestive heart failure","volume":"19","author":"Freeman","year":"2005","journal-title":"J Vet Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/1040638717711995","article-title":"Markers of oxidative stress in dogs with heart failure","volume":"29","author":"Verk","year":"2017","journal-title":"J Vet Diagn Invest"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12917-021-02878-x","article-title":"Inflammation and its association with oxidative stress in dogs with heart failure","volume":"17","author":"Nemec Svete","year":"2021","journal-title":"BMC Vet Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cvsm.2010.03.004","article-title":"The use of NT-proBNP assay in the management of canine patients with heart disease","volume":"40","author":"Oyama","year":"2010","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1939-1676.2004.tb02629.x","article-title":"Cardiac troponin-I concentration in dogs with cardiac disease","volume":"18","author":"Oyama","year":"2004","journal-title":"J Vet Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/jvim.12075","article-title":"Cardiac troponin-I concentration, myocardial arteriosclerosis, and fibrosis in dogs with congestive heart failure because of myxomatous mitral valve disease","volume":"27","author":"Falk","year":"2013","journal-title":"J Vet Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jvc.2011.11.005","article-title":"Echocardiographic assessment of canine degenerative mitral valve disease","volume":"14","author":"Chetboul","year":"2012","journal-title":"J Vet Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/hrt.2007.141002","article-title":"Two dimensional speckle tracking echocardiography: basic principles","volume":"96","author":"Blessberger","year":"2010","journal-title":"Heart"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3390\/ani15111523","article-title":"Speckle-tracking echocardiography in dogs: evaluating imaging parameters and methodological variability in global longitudinal strain assessment","volume":"15","author":"Mogensen","year":"2025","journal-title":"Animals (Basel)"},{"key":"ref24","first-page":"S38","article-title":"Nutritional therapy in the treatment of heart disease in dogs","volume":"6","author":"Dove","year":"2001","journal-title":"Altern Med Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvc.2025.12.004","article-title":"Assessment of combination cardiac supplements available in the United States for dogs with myxomatous mitral valve disease","author":"Bousquet","year":"2025","journal-title":"J Vet Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd2060","article-title":"Therapeutic potential of resveratrol: the in vivo evidence","volume":"5","author":"Baur","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.2174\/187152807781696464","article-title":"Anti-inflammatory responses of resveratrol","volume":"6","author":"Das","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/157489007780832560","article-title":"Resveratrol: a therapeutic promise for cardiovascular diseases","volume":"2","author":"Das","year":"2007","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/cells13201732","article-title":"Pleiotropic effects of resveratrol on aging-related cardiovascular diseases\u2014what can we learn from research in dogs?","volume":"13","author":"Grzeczka","year":"2024","journal-title":"Cells"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/antiox14020195","article-title":"Resveratrol ameliorates chronic stress in kennel dogs and mice by regulating gut microbiome and metabolome related to tryptophan metabolism","volume":"14","author":"Bian","year":"2025","journal-title":"Antioxidants"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/vcp.13101","article-title":"Analytical validation of a novel point-of-care immunoassay for canine N-terminal pro-brain natriuretic peptide analysis","volume":"51","author":"Harr","year":"2022","journal-title":"Vet Clin Pathol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1892\/0891-6640(2004)18<311:ASOMCM>2.0.CO;2","article-title":"Allometric scaling of M-mode cardiac measurements in normal adult dogs","volume":"18","author":"Cornell","year":"2004","journal-title":"J Vet Intern Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0002-9149(76)90491-4","article-title":"Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy","volume":"37","author":"Teichholz","year":"1976","journal-title":"Am J Cardiol"},{"key":"ref34","volume-title":"Bioenergetics and Growth","author":"Brody","year":"1945"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1740-8261.2002.tb01051.x","article-title":"Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier king Charles spaniels with and without left atrial enlargement","volume":"43","author":"Hansson","year":"2002","journal-title":"Vet Radiol Ultrasound"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"700230","DOI":"10.3389\/fvets.2021.700230","article-title":"Short-term effects of sacubitril\/valsartan on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve disease","volume":"8","author":"Saengklub","year":"2021","journal-title":"Front Vet Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/vcp.12268","article-title":"Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs and dogs with mitral valve degeneration","volume":"44","author":"Ruaux","year":"2015","journal-title":"Vet Clin Pathol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"H2181","DOI":"10.1152\/ajpheart.00554.2011","article-title":"Oxidative stress and heart failure","volume":"301","author":"Tsutsui","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1203480","DOI":"10.3389\/fvets.2023.1203480","article-title":"Evaluation of antioxidant status and lipid peroxidation in dogs with myxomatous mitral valve degeneration stage B1","volume":"10","author":"Tom\u0161i\u010d","year":"2023","journal-title":"Front Vet Sci."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/postgradmedj-2019-136415","article-title":"Therapeutic effect of resveratrol supplementation on oxidative stress: a systematic review and meta-analysis of randomised controlled trials","volume":"96","author":"Koushki","year":"2020","journal-title":"Postgrad Med J"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/iub.2020","article-title":"Vitamin E: regulatory role in the cardiovascular system","volume":"71","author":"Sozen","year":"2019","journal-title":"IUBMB Life"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.3390\/ani15172477","article-title":"Determination of retinol, cholecalciferol, \u03b1-tocopherol and phylloquinone levels in dogs with dilated cardiomyopathy: a preliminary study","volume":"15","author":"Bilgi\u00e7","year":"2025","journal-title":"Animals"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/antiox11081427","article-title":"Effects of coenzyme Q10 supplementation on oxidative stress markers, inflammatory markers, lymphocyte subpopulations, and clinical status in dogs with myxomatous mitral valve disease","volume":"11","author":"Druzhaeva","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jpba.2011.10.023","article-title":"Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC\u2013MS\/MS and their pharmacokinetics in dogs","volume":"59","author":"Muzzio","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/ijms25020747","article-title":"Resveratrol for the management of human health: how far have we come? A systematic review of resveratrol clinical trials to highlight gaps and opportunities","volume":"25","author":"Brown","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"298ra117","DOI":"10.1126\/scitranslmed.aaa7619","article-title":"Cancer chemoprevention: evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice","volume":"7","author":"Cai","year":"2015","journal-title":"Sci Transl Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1939-1676.2009.0428.x","article-title":"Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs","volume":"24","author":"Ljungvall","year":"2010","journal-title":"J Vet Intern Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1098-612X(03)00007-X","article-title":"Cardiac troponin I in cats with hypertrophic cardiomyopathy","volume":"5","author":"Connolly","year":"2003","journal-title":"J Feline Med Surg"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1892\/0891-6640(2002)016<0558:CTIIFH>2.3.CO;2","article-title":"Cardiac troponin I in feline hypertrophic cardiomyopathy","volume":"16","author":"Herndon","year":"2002","journal-title":"J Vet Intern Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1177\/1098612X211030218","article-title":"The feline cardiomyopathies: cardiomyopathies other than HCM","volume":"23","author":"Kittleson","year":"2021","journal-title":"J Feline Med Surg"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jvim.14897","article-title":"Transient myocardial thickening in cats associated with heart failure","volume":"32","author":"Novo Matos","year":"2018","journal-title":"J Vet Intern Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1590\/1678-4162-12991","article-title":"Correlation of malondialdehyde concentration with cardiac parameters of different stages of chronic mitral valve disease in dogs","volume":"75","author":"Almeida","year":"2023","journal-title":"Arq Bras Med Vet Zootec"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cvsm.2006.11.009","article-title":"Interpretation of liver enzymes","volume":"37","author":"Center","year":"2007","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12917-019-2169-1","article-title":"Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs","volume":"15","author":"Li","year":"2019","journal-title":"BMC Vet Res"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1867081\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:22:47Z","timestamp":1785943367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1867081\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":54,"alternative-id":["10.3389\/fvets.2026.1867081"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2026.1867081","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1867081"}}